Alto Neuroscience (NYSE:ANRO) vs. Appili Therapeutics (OTCMKTS:APLIF) Head-To-Head Review

Alto Neuroscience (NYSE:ANRO) and Appili Therapeutics (OTCMKTS:APLIF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Risk and Volatility

Alto Neuroscience has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Appili Therapeutics has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alto Neuroscience and Appili Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24 million	($2.42)	-11.09
Appili Therapeutics	$70,000.00	21.37	-$1.89 million	($0.03)	-0.38

Appili Therapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alto Neuroscience and Appili Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1	1	8	0	2.70
Appili Therapeutics	0	0	0	0	0.00

Alto Neuroscience presently has a consensus price target of $35.25, indicating a potential upside of 31.36%. Given Alto Neuroscience’s stronger consensus rating and higher probable upside, research analysts clearly believe Alto Neuroscience is more favorable than Appili Therapeutics.

Profitability

This table compares Alto Neuroscience and Appili Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Appili Therapeutics	N/A	N/A	-190.26%

About Alto Neuroscience

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

About Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.